Sovaprevir is an antiviral compound primarily studied for its potential use in the treatment of hepatitis C virus (HCV) infections. It belongs to the class of drugs known as NS3/4A protease inhibitors, which function by inhibiting the viral protease enzyme essential for the replication of the virus. This inhibition disrupts the processing of viral polyproteins, thereby preventing the formation of infectious viral particles. Sovaprevir is characterized by its specific chemical structure, which includes a series of functional groups that contribute to its activity and selectivity against HCV. The compound has been evaluated in various clinical trials, often in combination with other antiviral agents to enhance efficacy and reduce the likelihood of resistance. Its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are critical for determining dosing regimens and potential drug interactions. Overall, Sovaprevir represents a significant advancement in the development of targeted therapies for chronic hepatitis C, although its clinical use may vary based on ongoing research and regulatory approvals.

Sovaprevir

1001667-23-7: ACH 0141625, 2-Pyrrolidinecarboxamide, N-[(1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethenylcyclopropyl]-1-[(2S)-3,3-dimethyl-1-oxo-2-[2-oxo-2-(1-piperidinyl)ethyl]butyl]-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-, (2S,4R)-, Sovaprevir

Sovaprevir is a non-structural 3 (NS3) protease inhibitor with antiviral activity for the treatment of HCV infection.

CAS 1001667-23-7: Sovaprevir

Sovaprevir

Ref: 54-BUP12265

Sovaprevir

Ref: 4Z-S-491

Sovaprevir

Ref: TM-T28830